Business
Plandai Biotechnology Collaboration Offers Opportunity to Produce a Non-Psychoactive Cannabis Product for Medical Research
Plandai Biotechnology Collaboration Offers Opportunity to Produce a Non-Psychoactive Cannabis Product for Medical Research.
About this update from Plandai Biotechnology, Inc.
[{"type":"text","content":"\nPlandai Biotechnology Collaboration Offers Opportunity to Produce a Non-Psychoactive Cannabis Product for Medical Research\n\nPlandai Biotechnology Collaboration Offers Opportunity to Produce a Non-Psychoactive Cannabis Product for Medical Research\n\nNEW YORK, NY--(Marketwired - November 10, 2014) - Plandaí Biotechnology (OTCQB: PLPL) has entered into a collaboration agreement in Uruguay that will give the company the potential to produce a cannabis product with no psychoactive effects.  If successful, the company could then move forward with medical research investigating whether or not the product is efficacious in areas like cancer, post-traumatic stress disorder, concussions, epilepsy, concussions, multiple sclerosis, and neural diseases like Alzheimer's and Parkinson's.In September, Uruguay's Minister of Public Health agreed to sanction Plandaí's growing cannabis for medical research, through its wholly-owned subsidiary, Plandaí Biotechnology -- Uruguay, SA, in collaboration with the Group of Medicinal Chemistry from the School of Science at the University of the Republic in Montevideo, Uruguay.  The company can now legally grow cannabis in a supervised clinical environment, and with this collaboration, it won't be just CBD dominant strains of the drug; instead, Plandaí believes that it may be able to produce a cannabis profile that includes THC, which studies have suggested could yield medical benefits in multiple fields.While others in the industry are focused on producing a low-tetrahydrocannabinol (THC) cannabis product, in order to avoid the psychoactive effects, Plandaí believes this strategy ignores the potential benefits of the plant's principal psychoactive constituent or cannabinoid.  Instead, Plandaí plans to study the possible synergistic benefits of combining the full chemical profile of cannabis.There are a number of reasons that keep most entities away from THC altogether; including, the legal ramifications and the social stigma associated with the use of THC.  Many users of medicinal cannabis products want to realize the medical benefits of cannabis without the psychoactive side effects or the associated \"high\" with THC.  Plandaí, on the other hand, has an extraction process that works with live-plant matter and yields an extract that cont...